title: Interdiction of sphingolipid metabolism to improve standard cancer therapies.
abstract: Non-surgical therapies for human malignancies must negotiate complex cell signaling pathways to impede cancer cell growth, ideally promoting death of cancer cells while sparing healthy tissue. For most of the past half century, medical approaches for treating cancer have relied primarily on cytotoxic chemotherapeutics that interfere with DNA replication and cell division, susceptibilities of rapidly dividing cancer cells. As a consequence, these therapies exert considerable cell stress, promoting the generation of ceramide through de novo synthesis and recycling of complex glycosphingolipids and sphingomyelin into apoptotic ceramide. Radiotherapy of cancer exerts similar geno- and cytotoxic cell stresses, and generation of ceramide following ionizing radiation therapy is a well-described feature of radiation-induced cell death. Emerging evidence now describes sphingolipids as mediators of death in response to newer targeted therapies, cementing ceramide generation as a common mechanism of cell death in response to cancer therapy. Many studies have now shown that dysregulation of ceramide accumulation-whether by reduced generation or accelerated metabolism-is a common mechanism of resistance to standard cancer therapies. The aims of this chapter will be to discuss described mechanisms of cancer resistance to therapy related to dysregulation of sphingolipid metabolism and to explore clinical and preclinical approaches to interdict sphingolipid metabolism to improve outcomes of standard cancer therapies.
authors.affiliation: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA. beckham@musc.edu
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Beckham
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Cheng
authors.forename: S Tucker
authors.initials: ST
authors.lastname: Marrison
authors.forename: James S
authors.initials: JS
authors.lastname: Norris
authors.forename: Xiang
authors.initials: X
authors.lastname: Liu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013107:Sphingolipids / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D013107:Sphingolipids